Baxter enters definitive agreement to acquire all hemophilia-related assets Archemix

Baxter International Inc. (NYSE: BAX) announced today that it has entered into a definitive agreement to acquire all of the hemophilia-related assets of a privately-held biopharmaceutical company, Archemix, and entered into an exclusive license agreement for certain related intellectual property assets.

The lead product associated with the arrangement is ARC19499, a synthetic, subcutaneously-administered hemophilia therapy currently in a Phase I clinical trial in the UK. ARC19499 blocks Tissue Factor Pathway Inhibitor (TFPI) activity, thereby augmenting and improving blood clotting, potentially reducing replacement factor therapy for patients with hemophilia A and B.

"Baxter is committed to optimizing hemophilia care and improving the lives of people living with hemophilia around the world," said Hartmut Ehrlich, M.D., vice president, global research and development and medical affairs, for Baxter's BioScience business. "This anti-TFPI program is an important addition to other Baxter hemophilia development programs focusing on longer-acting rFVIII and rFIX and non-intravenous therapies."

Baxter expects to record a special pre-tax in-process research and development charge of approximately $30 million in the fourth quarter of 2010 relating to an upfront payment associated with the transaction. In the future, Baxter may also make milestone-related payments to Archemix of up to $285 million. Subject to regulatory approvals and other conditions, the companies expect to complete the transaction by year-end.

Source:

Baxter International Inc.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Baxter International Inc.. (2019, June 20). Baxter enters definitive agreement to acquire all hemophilia-related assets Archemix. News-Medical. Retrieved on February 03, 2023 from https://www.news-medical.net/news/20101119/Baxter-enters-definitive-agreement-to-acquire-all-hemophilia-related-assets-Archemix.aspx.

  • MLA

    Baxter International Inc.. "Baxter enters definitive agreement to acquire all hemophilia-related assets Archemix". News-Medical. 03 February 2023. <https://www.news-medical.net/news/20101119/Baxter-enters-definitive-agreement-to-acquire-all-hemophilia-related-assets-Archemix.aspx>.

  • Chicago

    Baxter International Inc.. "Baxter enters definitive agreement to acquire all hemophilia-related assets Archemix". News-Medical. https://www.news-medical.net/news/20101119/Baxter-enters-definitive-agreement-to-acquire-all-hemophilia-related-assets-Archemix.aspx. (accessed February 03, 2023).

  • Harvard

    Baxter International Inc.. 2019. Baxter enters definitive agreement to acquire all hemophilia-related assets Archemix. News-Medical, viewed 03 February 2023, https://www.news-medical.net/news/20101119/Baxter-enters-definitive-agreement-to-acquire-all-hemophilia-related-assets-Archemix.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post
You might also like...
Baxter to establish new innovation and R&D center in Cambridge, MA